Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor.
Saved in:
| Title: | Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor. |
|---|---|
| Authors: | Wainwright CE; Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia. Electronic address: Wainwright@health.qld.gov.au., Thorat T; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Conner S; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Quon BS; Centre for Heart Lung Innovation, St. Paul's Hospital, and Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada., Duckers J; Department of Respiratory Medicine, Cardiff and Vale University Health Board, NHS Wales, Cardiff, UK., Lou Y; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Mo C; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Xue Y; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Zhu L; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., McGarry L; Vertex Pharmaceuticals Incorporated, Boston, MA, USA. |
| Source: | Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2026 Mar; Vol. 25 (2), pp. 284-289. Date of Electronic Publication: 2025 Dec 05. |
| Publication Type: | Journal Article; Clinical Trial, Phase III |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101128966 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5010 (Electronic) Linking ISSN: 15691993 NLM ISO Abbreviation: J Cyst Fibros Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41350125 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Wainwright+CE%22">Wainwright CE</searchLink>; Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia. Electronic address: Wainwright@health.qld.gov.au.<br /><searchLink fieldCode="AU" term="%22Thorat+T%22">Thorat T</searchLink>; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Conner+S%22">Conner S</searchLink>; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Quon+BS%22">Quon BS</searchLink>; Centre for Heart Lung Innovation, St. Paul's Hospital, and Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.<br /><searchLink fieldCode="AU" term="%22Duckers+J%22">Duckers J</searchLink>; Department of Respiratory Medicine, Cardiff and Vale University Health Board, NHS Wales, Cardiff, UK.<br /><searchLink fieldCode="AU" term="%22Lou+Y%22">Lou Y</searchLink>; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Mo+C%22">Mo C</searchLink>; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Xue+Y%22">Xue Y</searchLink>; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Zhu+L%22">Zhu L</searchLink>; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22McGarry+L%22">McGarry L</searchLink>; Vertex Pharmaceuticals Incorporated, Boston, MA, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101128966%22">Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society</searchLink> [J Cyst Fibros] 2026 Mar; Vol. 25 (2), pp. 284-289. <i>Date of Electronic Publication: </i>2025 Dec 05. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase III – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>101128966 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-5010 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215691993%22">15691993 </searchLink><i>NLM ISO Abbreviation: </i>J Cyst Fibros <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41350125 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.jcf.2025.11.014 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 284 Titles: – TitleFull: Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Wainwright CE – PersonEntity: Name: NameFull: Thorat T – PersonEntity: Name: NameFull: Conner S – PersonEntity: Name: NameFull: Quon BS – PersonEntity: Name: NameFull: Duckers J – PersonEntity: Name: NameFull: Lou Y – PersonEntity: Name: NameFull: Mo C – PersonEntity: Name: NameFull: Xue Y – PersonEntity: Name: NameFull: Zhu L – PersonEntity: Name: NameFull: McGarry L IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: 2026 Mar Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1873-5010 Numbering: – Type: volume Value: 25 – Type: issue Value: 2 Titles: – TitleFull: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society Type: main |
| ResultId | 1 |